Product
Apatinib + Tislelizumab + Chemotherapy
1 clinical trial
1 indication
Indication
Gastric AdenocarcinomaClinical trial
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced Gastric and Gastroesophageal Junction(G/GEJ) Adenocarcinoma Patients With Poor Prognosis: A Prospective Exploratory StudyStatus: Completed, Estimated PCD: 2023-03-01